Link Pharma Chem Ltd.

Order Summary

Link Pharma Chem Ltd informed the exchange on October 13, 2026, about an order received from the GST Appellate Authority, Tribunal Vadodara, concerning the financial year 2021-2022.

Financial Impact of the Order

The order resulted in a substantial reduction in the GST demand and the associated penalty levied against the company.

Context of Alleged Violations

The order from the GST Appellate Authority addressed specific compliance observations for the FY 2021-2022 period:

• Tax Liability Discrepancy: A mismatch was identified between the tax liability declared in the GSTR1 filings and the tax paid through GSTR3B.
• Input Tax Credit (ITC): The authority cited excess ITC availed on the import of goods that was not reflected in GSTR-2A.

Management Commentary and Next Steps

Management has stated that the financial impact of the order, including the demand, penalty, and interest, does not have a material impact on the company. The company intends to appeal this order before the appropriate authority.

What This Means for Investors

This disclosure is a routine regulatory update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. While the order reduces the immediate financial liability, the ongoing process of appeal indicates that the matter remains subject to further legal or regulatory proceedings. Investors should monitor future updates regarding the outcome of the proposed appeal.

Compliance Update. Link Pharma Chem Ltd has filed its confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. ### RTA Confirmation. The company's Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime India Private Limited), issued the confirmation. The RTA verified that securities received for dematerialization during the quarter ended September 30, 2026, were processed and confirmed to the depositories. Security certificates received were mutilated and cancelled after due verification. The names of the depositories have been substituted in the register of members as the registered owner within the prescribed timelines. This filing ensures that the company remains in compliance with SEBI's requirements regarding the dematerialization of securities.

Re-appointment Details

Link Pharma Chem Ltd has re-appointed Mr. Satish G. Thakur as Chairman and Whole-time Director for a period of three years. The appointment became effective on June 24, 2026, and was ratified by shareholders during the Annual General Meeting held on August 20, 2026.

Director Profile

Mr. Satish G. Thakur has been associated with Link Pharma Chem Ltd since its incorporation. He possesses over 43 years of industry experience and holds a B.Sc. and L.Tech degree. His expertise lies in project design and development.

Governance and Relationships

Mr. Satish G. Thakur is the father of Mr. Rishikesh Thakur, who serves as the Managing Director of the company.

Board, Management, and Governance Update

Link Pharma Chem Ltd (BSE: 524748) has formally announced the re-appointment of Mr. Rishikesh Thakur as the Managing Director of the company.

Key Terms and Details

• Appointee: Mr. Rishikesh Thakur (DIN: 08777265)
• Term: 3 Years
• Effective Date: September 24, 2026
• Approval: Confirmed via resolution at the Annual General Meeting held on August 20, 2026

Profile Background

Mr. Rishikesh Thakur holds a B. Eng. in Polymer from London Metropolitan University. He possesses over 15 years of experience in the chemical business, covering manufacturing, Research & Development, project management, and new business development. He previously joined the company as General Manager – Operations, where he oversaw complete business activity.

Relationship Disclosure

Mr. Rishikesh Thakur is the son of Mr. Satish G. Thakur, who currently serves as the Chairman and Whole-time Director of the company.

What This Means for Investors

This announcement confirms the continuity of leadership for the company. As the re-appointment was passed through a resolution at the Annual General Meeting, it represents a standard procedural process for retaining executive leadership rather than a strategic management shift. Existing shareholders should view this as a stable continuation of the current organizational structure.

41st Annual General Meeting Outcome

Link Pharma Chem Ltd (BSE: 524748) conducted its 41st Annual General Meeting (AGM) on August 20, 2026, through video conferencing. The company reported that all six resolutions proposed in the AGM notice were approved by the shareholders with the requisite majority. The voting process, managed by M/s. Vijay Bhatt & Co. as the scrutinizer, included both remote e-voting and electronic voting during the meeting.

Voting Summary

Across all six resolutions, the voting turnout and pattern remained consistent. Shareholders expressed strong support for the management's proposals.

Resolutions Passed

The resolutions covered both standard financial adoption and key management appointments:

• Financial Adoption: Consideration and adoption of the Audited Financial Statements for the financial year ended March 31, 2026, along with the Board and Auditors' reports.
• Director Appointment: Appointment of a director in place of Mr. Satish Thakur, who retired by rotation and was eligible for re-appointment.
• Audit Ratification: Ratification of the remuneration for the Cost Auditors for the financial year 2026-2027.
• Secretarial Audit: Appointment of the Secretarial Auditor.
• Management Re-appointments:
  • Special Resolution for the re-appointment of Mr. Satish G. Thakur as Chairman & Whole-time Director.
  • Special Resolution for the re-appointment of Mr. Rishikesh Thakur as Managing Director.

Investor Takeaway

The successful conclusion of the 41st AGM indicates stability in the company's governance and the continuation of the current leadership team. Shareholders have formally approved the financial statements and audit-related appointments for the upcoming fiscal cycle, confirming continuity in operations and management oversight.

AGM Voting Results

Link Pharma Chem Limited held its 41st Annual General Meeting (AGM) on August 20, 2026, via Video Conferencing (VC) and Other Audio-Visual Means (OAVM). The company submitted the Consolidated Scrutinizer's Report, confirming that all six resolutions proposed in the AGM notice were passed with the requisite majority.

Resolutions Passed

The following resolutions were approved by shareholders:

• Resolution 1 (Ordinary): Adoption of Audited Financial Statements for the financial year ended March 31, 2026, and the Reports of the Board of Directors and Auditors.
• Resolution 2 (Ordinary): Appointment of a director in place of Mr. Satish Thakur, who retired by rotation and was re-appointed.
• Resolution 3 (Ordinary): Ratification of remuneration for Cost Auditors for the financial year 2026-2027.
• Resolution 4 (Ordinary): Appointment of the Secretarial Auditor.
• Resolution 5 (Special): Re-appointment of Mr. Satish G. Thakur as Chairman & Whole-time Director.
• Resolution 6 (Special): Re-appointment of Mr. Rishikesh Thakur as Managing Director.

Voting Overview

According to the Scrutinizer's Report, voting was conducted via remote e-voting and electronic voting during the AGM. Participation included 47 shareholders (3 from the Promoter/Promoter Group and 44 Public shareholders) attending via video conferencing. All resolutions passed with significant majority support (approximately 99.74% in favor vs. 0.26% against).

Investor Takeaway

This filing represents the successful completion of the company's 41st AGM. For shareholders, the outcome indicates continuity in the board and management structure, alongside the routine approval of statutory audit and remuneration ratifications. There were no contested outcomes reported in the voting results.

Meeting Overview

Link Pharma Chem Ltd held its 41st Annual General Meeting (AGM) on August 20, 2026, through Video Conferencing and Other Audio-Visual Means. The meeting was attended by 47 members and chaired by Mr. Satish G. Thakur, Whole-time Director. The proceedings commenced at 11:40 a.m. and concluded at 12:05 p.m.

Business Transacted

The shareholders considered and transacted the following items:

Proceedings and Reporting

The company confirmed that the notice of the AGM, Annual Accounts, and Board's Report were taken as read. Management noted that there were no qualifications, observations, or comments in the Auditor's report. The Chairman provided an overview of the company's performance for the 2025-2026 financial year, current business activities, and future outlook.

Q&A Session

The meeting included a Q&A session for shareholders. Out of 8 members who requested to speak, 5 were present to pose their queries. Mr. Rishikesh Thakur, Managing Director, addressed the raised questions.

Voting and Scrutiny

Remote e-voting was available to members from August 17, 2026, at 9:00 a.m. to August 19, 2026, at 5:00 p.m. Additionally, an e-voting facility was provided during the meeting for those who had not voted remotely. Mr. Vijay Bhatt of Vijay Bhatt & Co. was appointed as the scrutinizer to compile the results of both the remote e-voting and the e-voting conducted during the meeting. The final consolidated report will be placed on the company's website and submitted to the BSE.

Regulatory Disclosure

Link Pharma Chem Ltd has published an extract of its unaudited financial results for the quarter ended June 30, 2026. This announcement serves as a regulatory requirement to keep stakeholders and the public informed about the company's financial status.

Publication Details

The company confirmed the publication of these results in the following newspapers on August 6, 2026:

• Business Standard (English Edition)
• Loksatta (Gujarati Edition)

Compliance Context

This filing is performed in strict adherence to Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed entities to publish financial results in newspapers to enhance transparency and accessibility of financial information for shareholders.

Investor Takeaway

This update is a procedural compliance matter and does not represent a new business development, financial event, or operational update. Investors should view this as standard adherence to regulatory requirements.

Financial Snapshot

Revenue and Income Analysis

The company witnessed sequential and year-over-year revenue growth. Revenue from operations for the quarter ended June 30, 2026, stood at ₹8.77 crore (₹876.84 lakh), reflecting an increase over the ₹6.59 crore (₹658.88 lakh) reported in the March 2026 quarter and ₹7.81 crore (₹781.48 lakh) in the June 2025 quarter. Total income for the current quarter reached ₹9.12 crore (₹911.73 lakh).

Profitability Analysis

Link Pharma Chem returned to profitability this quarter. The company reported a profit after tax of ₹0.32 crore (₹31.83 lakh) for the quarter ended June 30, 2026, a significant recovery from the loss of ₹0.41 crore (₹40.86 lakh) posted in the previous quarter ended March 31, 2026. The profit before tax was recorded at ₹0.39 crore (₹38.87 lakh).

Exceptional or One-Time Impact

Management highlighted that in accordance with Ind AS 109, investments are valued at market prices, and differences between cost and market value are recorded as 'Other Income'.

• Other Income: Reported at ₹0.35 crore (₹34.89 lakh) for the current quarter.
• Fair Value Impact: This figure includes a fair value net gain of ₹0.18 crore (₹18.47 lakh) arising on financial assets designated at FVTPL, contributing to the volatility in non-operating income.

Concerns and Watch Points

What This Means for Investors

The results for the quarter ended June 30, 2026, indicate a operational recovery with the company shifting back to profitability. While the top-line growth is positive, investors should be mindful that a portion of the 'Other Income' is driven by fair value fluctuations of investments, which may not recur consistently. Tracking sustainable growth in operational margins will be key moving forward.

Investor Takeaway

Link Pharma Chem Ltd. has shown a positive turnaround in its financial performance for the first quarter of the fiscal year 2026-27. With a return to profit and growth in revenue from operations, the company is demonstrating signs of stability compared to the previous quarter. However, investors are advised to distinguish between operational profit and the non-operating income derived from financial asset valuations, as disclosed in the notes to accounts. Ongoing monitoring of core chemical manufacturing activities and cost management will be essential.

Financial Snapshot

Profitability Analysis

Link Pharma Chem Ltd. demonstrated a sequential turnaround in the quarter ended June 30, 2026. After posting a loss of 40.86 in the March 2026 quarter, the company moved to a profit of 31.83 in the current quarter. However, when compared to the same period in the previous year (June 2025), net profit shows a decline from 40.19 to 31.83.

Revenue and Income Analysis

Total income for the quarter was 911.73. Other Income significantly impacted the results this period. The company reported 'Fair value Net Gain arising on financial asset designated as at FVTPL' of 18.47 for the quarter ended June 30, 2026, compared to a loss of 2.86 in the previous quarter. Excluding this fair value component, the adjusted Other Income for the current quarter stood at 16.42, compared to 17.59 in the preceding quarter.

Concerns and Watch Points

What This Means for Investors

The company has successfully navigated out of a loss-making quarter, returning to profitability in the first quarter of the new fiscal year. The primary development for investors is the sequential recovery in the bottom line, though the profit level has not yet matched the performance seen in the corresponding quarter last year. The presence of fair value gains in Other Income highlights the importance of distinguishing between operational and non-operational income when assessing the company's core business performance.

Investor Takeaway

Link Pharma Chem has shown a positive trend by moving back into profitability. Investors should focus on the sustainability of this operational turnaround in subsequent quarters. Tracking the company's core manufacturing performance while keeping an eye on the volatility introduced by financial asset valuations will be essential for assessing long-term health.

AGM Schedule and Participation Details

Link Pharma Chem Ltd. has scheduled its 41st Annual General Meeting (AGM) for Thursday, August 20, 2026, at 11:30 AM (IST). The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

Important Dates

The e-voting cut-off date for participation is August 13, 2026. Remote e-voting is set to commence on Monday, August 17, 2026, at 9:00 AM (IST) and will conclude on Wednesday, August 19, 2026, at 5:00 PM (IST).

Shareholder Compliance and KYC Updates

The company has reminded shareholders, particularly those holding physical securities, to update their KYC details including PAN, address, mobile number, bank account information, and nomination choices. This requirement is in accordance with the SEBI Master Circular dated May 07, 2024. Management emphasized that physical security holders must dematerialize their securities to remain eligible for any payments, including dividends, effective from April 1, 2024.

Annual Report Access

The company has dispatched the Annual Report for the financial year 2025-2026 to shareholders who have not yet registered their email addresses. Shareholders are encouraged to register their email addresses with the company or their depository participant to support the company's Green Initiative and ensure seamless electronic communication.

Annual General Meeting Details

Link Pharma Chem Limited will hold its 41st Annual General Meeting (AGM) on Thursday, 20th August, 2026, at 11:30 a.m. (IST). In compliance with regulatory guidelines and MCA circulars, the meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM), without the physical presence of members at a common venue. The company's registered office is deemed to be the venue for the meeting.

Book Closure and E-Voting

The company has set the book closure period for the purpose of the 41st AGM from Friday, 14th August, 2026, to Thursday, 20th August, 2026 (both days inclusive).

Shareholders will be provided the facility to exercise their right to vote through electronic means. The remote e-voting period is scheduled to commence on Monday, 17th August, 2026, at 09:00 a.m. and will conclude on Wednesday, 19th August, 2026.

Investor Takeaway

This announcement is a routine corporate governance update. Existing shareholders should note the AGM date for virtual attendance and the specified e-voting window to exercise their voting rights. The company has published this notice in accordance with Regulation 47 of the SEBI (LODR) Regulations, 2015, and Section 108 of the Companies Act, 2013.

Board Meeting Update

Link Pharma Chem Ltd has formally notified the exchange regarding the schedule for its upcoming Board of Directors meeting. The board is set to meet to deliberate on and approve the company's financial performance for the first quarter of the financial year.

Regulatory Compliance and Trading Window

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, the company has implemented a closure of its trading window for designated persons. This measure is a standard governance practice to prevent insider trading ahead of material financial disclosures.

What This Means for Investors

This announcement serves as a precursor to the company's official financial results release. Investors should monitor the company's upcoming disclosures following the board meeting on August 05, 2026, to understand the financial performance for the quarter ended June 30, 2026. The trading window restriction is a routine compliance matter and does not provide an indication of the upcoming results.

Key Highlights

Link Pharma Chem Ltd has formally intimated the schedule for its 41st Annual General Meeting. The company will conduct the meeting through virtual means to facilitate shareholder participation.

Important Dates

The company has finalized the following schedule for book closure and e-voting eligibility:

Corporate Action Details

The company will keep its Register of Members and Share Transfer Books closed from Friday, 14th August 2026, to Thursday, 20th August 2026 (both days inclusive). This action is taken for the purpose of the 41st Annual General Meeting. During this period, share transfer processing will remain suspended in accordance with standard regulatory practices.

What This Means for Investors

This filing is a procedural update required under the Companies Act, 2013, and SEBI regulations. Investors intending to vote on the business to be transacted at the AGM should note the cut-off date of 13th August 2026. Shareholders holding shares as of this date, either in physical or dematerialized form, are eligible to cast their votes electronically.

Investor Takeaway

The update provided by Link Pharma Chem Ltd is administrative in nature, confirming the dates for the upcoming 41st Annual General Meeting. There is no new financial, operational, or strategic data released in this filing. Shareholders should mark their calendars for the cut-off date of 13th August 2026 if they wish to participate in the remote e-voting process.

Key Highlights

• Financial Turnaround: The company reported a net profit of ₹0.08 crore (₹7.69 lakh) for FY 2025-26, compared to a net loss of ₹1.03 crore (₹102.73 lakh) in the previous year.
• Revenue Growth: Revenue from operations grew by 7.86% year-on-year to ₹27.43 crore (₹2743.15 lakh).
• Leadership Continuity: The board re-appointed Mr. Satish G. Thakur as Chairman & Whole-time Director and Mr. Rishikesh Thakur as Managing Director for a three-year term effective from mid-2026.
• Tax Litigation: GST-related indirect tax litigation increased significantly to ₹1.55 crore (₹154.59 lakh) as of March 31, 2026.

Financial Snapshot

Profitability Analysis

The company achieved a positive net profit of ₹0.08 crore (₹7.69 lakh) in FY 2025-26, reversing the net loss of ₹1.03 crore (₹102.73 lakh) incurred in FY 2024-25. This performance is reflected in an EPS of ₹0.17 for FY 2025-26, compared to a negative EPS of ₹2.31 in the previous year.

Corporate Action Details

The company did not recommend a dividend for FY 2025-2026. The board has approved the re-appointment of Mr. Satish G. Thakur as Chairman & Whole-time Director (for the period 24/06/2026 to 23/06/2029) and Mr. Rishikesh Thakur as Managing Director (for the period 24/09/2026 to 23/09/2029).

Legal, Penalty, or Regulatory Update

As of March 31, 2026, the company disclosed indirect tax litigation under the GST Act amounting to ₹1.55 crore (₹154.59 lakh), a substantial increase from ₹0.08 crore (₹8.35 lakh) reported in the previous year. The management has also been advised by auditors to update the audit trail (edit log) facilities specifically for inventory records.

Concerns and Watch Points

Investor Takeaway

Link Pharma Chem Limited has demonstrated a notable turnaround in its financial performance, moving back to profitability in the current fiscal year. The revenue growth of 7.86% indicates stable market demand for its chemical intermediates. Leadership continuity is assured with the re-appointment of the top management team. However, investors should closely monitor the rising GST-related litigation, which represents a contingent financial liability, and track management's ongoing R&D efforts to improve product yields and control operational costs in a volatile raw material environment.

Key Highlights

Important Figures Used

Management Re-appointments

The company has proposed the following leadership re-appointments for three-year terms, subject to shareholder approval:

• Mr. Satish G. Thakur: Re-appointed as Chairman & Whole-time Director, effective June 24, 2026.
• Mr. Rishikesh Thakur: Re-appointed as Managing Director, effective September 24, 2026.

Auditor Updates

• Cost Auditor: M/s. Y. S. Thakar & Co. has been appointed as Cost Auditor for the financial year 2026-2027, with remuneration ratified at ₹0.00045 crore (₹0.45 lakh) per annum.
• Secretarial Auditor: Vijay Bhatt & Co. has been appointed for a four-year term covering the financial years 2026-2027 to 2029-2030.

Concerns and Watch Points

What This Means for Investors

The 41st AGM notice outlines standard corporate governance procedures, including the renewal of key executive positions and auditor appointments. Investors holding physical share certificates should prioritize the KYC compliance update to ensure their folios remain active and eligible for service requests or dividend payouts. The meeting will be held virtually, consistent with recent regulatory trends for corporate compliance.

Compliance Update

Link Pharma Chem Ltd has completed its compliance filing for the quarter ended June 30, 2026, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Confirmation

The company has confirmed, through its Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited, that all securities received for dematerialization during the quarter were processed correctly. This includes the following aspects:

• Timely Processing: All requests for dematerialization were accepted or rejected within the required regulatory timelines.
• Verification: The certificates received were mutilated and cancelled after due verification by the depository participant.
• Listing: The securities comprised in the certificates have been listed on the stock exchanges where the company's earlier issued securities are already listed.

This filing serves as standard operational confirmation, ensuring that the company maintains compliance with its regulatory obligations regarding shareholder services and depository participants.

Summary

• Link Pharma Chem Limited has submitted a confirmation certificate regarding the dematerialization of its securities.
• The filing is for the quarter ended March 31, 2026, and was sent to the Department of Corporate Services, BSE Limited.
• MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent, issued the confirmation, verifying compliance with SEBI regulations.

Key Numbers & Dates

• Quarter Ended: March 31, 2026
• Confirmation Certificate Date (MUFG): April 03, 2026
• Filing Date (Link Pharma to BSE): April 08, 2026
• Scrip Code: 524748

What Changes for the Business

• The confirmation assures that the dematerialization process, including security handling, certificate cancellation, and member register updates, has been conducted according to SEBI regulations during the specified quarter.

Summary

• Link Pharma Chem Limited has announced the closure of its trading window for dealing in company securities.
• This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct.
• The trading window will reopen 48 hours after the declaration of the Audited Financial Results for the quarter and year ending March 31, 2026.

Key Numbers & Dates

• Trading Window Closure Starts: 01 April 2026
• Financial Results Period: Quarter and year ending 31 March 2026
• Trading Window Reopens: 48 hours after declaration of Audited Financial Results
• Letter Date: 26 March 2026

What to Track Next

• The date of the Board Meeting where the Audited Financial Results will be considered will be intimated in due course.

Omkar Pharmachem Limited, Avance Technologies Limited, Link Pharma Chem Limited, and Gemstone Investments Limited have released their standalone and/or consolidated unaudited financial results for the quarter and nine months ending December 31, 2025. These publications include key figures like total income, net profit, and earnings per share, comparing them with previous periods. Separately, Aditya Birla Housing Finance Limited has issued demand notices under the SARFAESI Act against specific borrowers for loan defaults. The Mehsana Urban Co-operative Bank Ltd. has also taken possession of property under the SARFAESI Act due to a borrower's default.

Link Pharma Chem Limited, Omkar Pharmachem Limited, Avance Technologies Limited, and Gemstone Investments Limited have released extracts of their unaudited financial results for the quarter and nine months ended December 31, 2025. These advertisements were published in newspapers between February 14th and 16th, 2026, adhering to SEBI's Listing Obligations and Disclosure Requirements, and provide key financial metrics for the periods.

News Crux

Announcement of unaudited financial results for Q3 FY26 and 9M FY26. Board approved the results. Auditors provided a limited review report. Update on Labour Codes.

Quarterly Results

Standalone ResultsQ3 FY26 vs Q3 FY25 (YoY):

• Revenue from operations: ₹673.47 Lakhs (↑ 26.06%) vs ₹534.24 Lakhs
• Total Income: ₹653.37 Lakhs (↑ 36.66%) vs ₹478.09 Lakhs
• Profit Before Tax (PBT): ₹10.32 Lakhs vs (₹89.09 Lakhs)
• Net Profit (PAT): ₹6.82 Lakhs vs (₹66.71 Lakhs)
• EPS (Basic & Diluted): ₹0.15 vs (₹1.50)

Q3 FY26 vs Q2 FY26 (QoQ):

• Revenue from Operations: ₹673.47 Lakhs (↑ 6.99%) vs ₹629.32 Lakhs
• Total Income: ₹653.37 Lakhs (↑ 3.04%) vs ₹634.10 Lakhs
• Profit Before Tax (PBT): ₹10.32 Lakhs (↑ 738.94%) vs ₹1.23 Lakhs
• Net Profit (PAT): ₹6.82 Lakhs (↑ 337.18%) vs ₹1.56 Lakhs
• EPS (Basic & Diluted): ₹0.15 vs ₹0.03

Exceptional Items: No specific exceptional items were highlighted. 'Other Income' in Q3 FY26 was negative at ₹(20.10) Lakhs, compared to positive in Q2 FY26 (₹4.78 Lakhs) and negative in Q3 FY25 (₹(56.16) Lakhs). This impacted Total Income. Note 3 clarifies this relates to fair value changes on financial assets.

Financial Deep Dive

Income Statement Drivers: Revenue from operations demonstrated robust year-on-year growth of 26.06%. The primary driver for the significant turnaround in profitability from losses to profits was the substantial improvement in PBT and PAT YoY. Total Income also saw a strong increase YoY, partly influenced by the movement in 'Other Income'. Total expenses reduced YoY, further aiding profitability.

Balance Sheet/Debt/Cash Flow: The provided text does not contain details regarding the company's balance sheet, net debt, or cash flow statement for the period.

Key Events

Board of Directors met and approved the unaudited financial results for Q3 FY26 and 9M FY26, along with the Limited Review Report from statutory auditors CNK & Associates LLP. The company also noted the assessment of the new Labour Codes.

Labour Codes Update

The company has assessed the new Labour Codes effective November 21, 2025. They concluded that there is no material financial impact on the current financial statements. Further assessment on employee benefit expenses will be undertaken upon notification of relevant rules by appropriate authorities.

News Crux

Board of Directors of Link Pharma Chem Limited approved the unaudited financial results for the quarter and nine months ended December 31, 2025, on February 14, 2026.

Quarterly Results

Standalone results for the quarter and nine months ended December 31, 2025:

Quarter ended December 31, 2025 vs December 31, 2024 (YoY):

• Revenue from operations: ₹673.47 Lakhs, a 26.06% increase from ₹534.24 Lakhs.
• Total Income: ₹653.37 Lakhs, a 36.66% increase from ₹478.09 Lakhs.
• Net Profit/(Loss): ₹6.82 Lakhs, a turnaround from a net loss of ₹66.71 Lakhs.

Quarter ended December 31, 2025 vs September 30, 2025 (QoQ):

• Revenue from operations: ₹673.47 Lakhs, a 6.99% increase from ₹629.32 Lakhs.
• Total Income: ₹653.37 Lakhs, a 3.04% increase from ₹634.10 Lakhs.
• Net Profit/(Loss): ₹6.82 Lakhs, a 337% increase from ₹1.56 Lakhs.

Nine Months Ended December 31, 2025 vs December 31, 2024 (YoY):

• Revenue from operations: ₹2,084.27 Lakhs, a 9.77% increase from ₹1,898.68 Lakhs.
• Total Income: ₹2,089.87 Lakhs, a 9.67% increase from ₹1,905.54 Lakhs.
• Net Profit/(Loss): ₹28.55 Lakhs, a turnaround from a net loss of ₹67.71 Lakhs.

Earnings Per Share (EPS):

• Q3 FY26: ₹0.15 (vs ₹-1.50 in Q3 FY25)
• 9M FY26: ₹0.64 (vs ₹-1.52 in 9M FY25)

No exceptional items were explicitly identified as one-off gains or losses, however, "Other Income" for Q3 FY26 included a fair value loss of ₹20.29 Lakhs.

Financial Deep Dive

• Revenue from operations showed year-on-year growth in Q3 FY26.
• The company's profit before tax and net profit saw a significant turnaround from losses in the previous year's comparable periods.
• Q3 FY26 Net Profit was impacted by a fair value loss of ₹20.29 Lakhs on financial assets designated as FVTPL, which is consistent with the nature of 'Other Income' reported by the company.
• The company assessed the impact of new Labour Codes, which became effective from November 21, 2025, and concluded there is no material financial impact on its financial statements as of December 31, 2025.

Key Events

• Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, on February 14, 2026.
• The company noted the effectiveness of new Labour Codes from November 21, 2025, and assessed no material financial impact on its current statements.

Link Pharma Chem Limited has issued a corporate announcement intimating the market about an upcoming Board Meeting scheduled for February 14, 2026. The primary agenda for this meeting is the consideration and approval of the company's unaudited financial results for the third quarter and the cumulative nine-month period that concluded on December 31, 2025. This filing serves as a procedural notice, setting the stage for the disclosure of financial performance. In adherence to SEBI regulations and the company's code of conduct, the trading window for designated persons, which commenced on January 1, 2026, will continue to remain closed. It is slated to reopen only 48 hours following the official declaration of these financial results. No specific financial figures, management guidance, or future outlook are provided in this particular announcement. Investors will await the detailed results post-board meeting for insights.

Link Pharma Chem Limited has been served a demand order by the Assistant Commissioner, Central GST & Central Excise, Vadodara. The order necessitates the payment of GST amounting to ₹1,05,21,897/- for the financial year 2021-2022, alongside applicable interest and penalty. Additionally, the company is directed to recover excess availed Input Tax Credit (ITC) of ₹11,29,639/- for the same period, also subject to interest and penalty. The alleged contraventions cited for these demands include a mismatch between tax liability declared in GSTR1 and tax paid through GSTR3B, as well as excess ITC claimed on the import of goods not reflected in GSTR-2A. Link Pharma Chem Limited has communicated that the financial impact is confined to the extent of the demand, penalty, and interest imposed, but they maintain that there is no 'material impact' on the company's overall operations. Consequently, the company has declared its intention to file an appeal with the appropriate authority against this order.

Link Pharma Chem Limited has submitted a regulatory filing to the Bombay Stock Exchange (BSE) containing a Confirmation Certificate as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended December 31, 2025.

The Certificate has been received from the company's Registrar and Share Transfer Agent (RTA), M/s. MUFG Intime India Private Limited (formerly Link Intime India Private Limited). It confirms that all securities received from depository participants for dematerialisation during the specified quarter were processed accordingly. This includes confirmation of acceptance or rejection to the depositories and verification that the dematerialised securities have been listed on the stock exchanges.

Furthermore, the RTA confirmed that physical share certificates received for dematerialisation were properly mutilated and cancelled after due verification. The process also involved substituting the depositories' names in the company's register of members as the registered owner within the prescribed timelines. This routine compliance filing ensures the integrity of share transfer processes and adherence to SEBI's regulations governing depositories and participants.

Link Pharma Chem Limited has announced its unaudited financial results for Q1 FY26 and Q2 FY26, alongside its audited annual report for FY25 and various corporate actions.

Quarterly and Annual Performance:

• Q1 FY26 (ended June 30, 2025): The company posted revenue from operations of ₹781.48 Lakhs, a year-on-year decline of 11.66% from ₹884.63 Lakhs in Q1 FY25. However, Profit After Tax (PAT) saw a substantial increase of 35.60% YoY, reaching ₹40.19 Lakhs from ₹29.64 Lakhs. The Earnings Per Share (EPS) grew by 35.8% YoY to ₹0.91. Sequentially, revenue increased by 21.2% from Q4 FY25.
• Q2 FY26 (ended September 30, 2025): Revenue from operations grew by 31.15% year-on-year to ₹629.32 Lakhs from ₹479.82 Lakhs in Q2 FY25. The net loss for the quarter narrowed significantly to ₹1.56 Lakhs, an improvement from a loss of ₹30.63 Lakhs in the corresponding period last year. The EPS turned positive at ₹0.03.
• H1 FY26 (ended September 30, 2025): The company reported a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a significant turnaround from a net loss of ₹0.99 Lakhs in H1 FY25. The EPS for the half-year stood at ₹0.94.
• FY25 (ended March 31, 2025): The annual report revealed a revenue of ₹2543.34 Lakhs, a 14.93% decrease from ₹2989.77 Lakhs in FY24. The net loss for FY25 was ₹102.73 Lakhs, which was an improvement from the ₹136.29 Lakhs loss reported in FY24. The TTM Net Profit is reported at -₹0.60 Lakhs with an EPS of -₹1.35.

Financial Deep Dive:

• Income Statement Drivers: While annual net losses persist, the quantum has reduced. Quarterly performance shows a mixed trend with recovery in Q2 FY26's revenue and significant loss containment. Historical annual ROCE is negative (-3.00% as per latest available data in company_data), and ROE is -7.81%.
• Balance Sheet: As of March 2025, total borrowings were ₹5.78 Cr, with a Debt-to-Equity ratio of 0.62. The company reported net debt of ₹8.10 Cr.
• Cash Flow: The FY25 annual report summary indicated that operational cash flow turned positive. For FY25, operating cash flow was ₹2.69 Cr, and capital expenditure on fixed assets was ₹0.26 Cr.

Outlook and Discussion:

The annual report highlights a strategic focus on specialty chemicals. However, the company faces risks including feedstock price volatility and fluctuations in market demand.

Key Events:

• Director Re-appointment: Mrs. Rachna Manav Ghai was re-appointed as a Woman Independent Director for a second term of five years (September 14, 2025, to September 13, 2030), subject to shareholder approval, which was obtained at the 40th AGM.
• Company Secretary Changes: Ms. Khushbu Prakashbhai Patel resigned as Company Secretary and Compliance Officer, effective December 16, 2025. Mrs. Komal Bhojwani has been appointed as the new Company Secretary and Compliance Officer, effective January 1, 2026.
• Annual General Meeting (AGM): The 40th AGM was held on September 9, 2025, where all presented resolutions, including the adoption of FY25 financial statements and director re-appointments, were unanimously passed.
• Regulatory Filings: A trading window closure was announced effective October 1, 2025, and subsequently extended from January 1, 2026, pending Q3 FY26 results. A confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018, was submitted. The company is exempt from disclosing Related Party Transactions for H1 FY26 due to its size.

Link Pharma Chem Limited announced its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26) and September 30, 2025 (Q2 FY26), alongside its annual report for FY2024-2025.

In Q1 FY26, the company reported revenue from operations of ₹781.48 Lakhs, a year-on-year decline of 11.66% from ₹884.63 Lakhs in Q1 FY25. However, Profit After Tax (PAT) saw a significant improvement, growing by 35.60% YoY to ₹40.19 Lakhs from ₹29.64 Lakhs. The company also turned profitable quarter-on-quarter, recovering from a loss in the previous quarter.

For Q2 FY26, Link Pharma Chem reported revenue from operations of ₹629.32 Lakhs, an increase of 31.15% year-on-year from ₹479.82 Lakhs in Q2 FY25. The net loss for the quarter narrowed substantially to ₹1.56 Lakhs, an improvement from a loss of ₹30.63 Lakhs in the corresponding period last year. Earnings Per Share (EPS) for Q2 FY26 turned positive at ₹0.03.

For the first half of FY26 (H1 FY26), the company achieved a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a substantial turnaround from a net loss of ₹0.99 Lakhs in H1 FY25. The H1 FY26 EPS stood at ₹0.94.

The Annual Report for FY2024-2025 indicated a revenue of ₹2543.34 Lakhs, a decrease of 14.93% from ₹2989.77 Lakhs in FY24. The net loss for FY25 was ₹102.73 Lakhs, an improvement from ₹136.29 Lakhs in FY24. The report noted that operational cash flow turned positive and net debt reduced significantly.

In terms of corporate actions, the Board approved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second term of five years (September 14, 2025, to September 13, 2030), subject to shareholder approval. Shareholders unanimously passed all resolutions at the 40th Annual General Meeting (AGM) held on September 9, 2025, including the adoption of FY25 financials and director re-appointments.

The company's outlook includes a focus on specialty chemicals, with identified risks such as feedstock price volatility and market demand fluctuations. Regulatory updates included the closure of the trading window effective October 1, 2025, and the appointment of Mrs. Komal Bhojwani as Company Secretary and Compliance Officer, effective January 1, 2026, following the resignation of Ms. Khushbu Prakashbhai Patel.

Link Pharma Chem Limited has announced a key personnel change in its corporate governance structure with the appointment of Mrs. Komal Bhojwani as the new Company Secretary and Compliance Officer. This appointment, effective from January 1, 2026, was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee. Mrs. Bhojwani is an Associate Member of the Institute of Company Secretaries of India, holds a Bachelor's degree in Commerce and Law, and possesses over four years of post-qualification experience in corporate laws.

This appointment follows the resignation of the previous Company Secretary and Compliance Officer, Ms. Khushbu Prakashbhai Patel, whose cessation is effective December 16, 2025. The timely appointment aims to ensure smooth transitions and maintain regulatory adherence.

In terms of financial performance, the company's recent unaudited results for the second quarter (Q2 FY26) ended September 30, 2025, showed a revenue increase of 31.15% year-on-year to ₹629.32 Lakhs. The net loss for the quarter significantly narrowed to ₹1.56 Lakhs, an improvement from a loss of ₹30.63 Lakhs in the corresponding prior-year period, with Earnings Per Share (EPS) turning positive at ₹0.03. For the first half of FY26, Link Pharma Chem achieved a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a substantial turnaround from a net loss in H1 FY25, and reported an EPS of ₹0.94.

Earlier, for FY25, the company reported an annual revenue of ₹2543.34 Lakhs, a 14.95% decrease YoY, but its net loss improved to ₹102.73 Lakhs from ₹136.29 Lakhs in FY24. The company's strategic outlook includes a focus on specialty chemicals, with identified risks such as feedstock price volatility and market demand fluctuations.

Link Pharma Chem Limited has announced the closure of its trading window for dealing in the company's securities, effective January 1, 2026. This closure will remain in effect until 48 hours after the declaration of its unaudited financial results for the quarter and nine months ending December 31, 2025. The date of the Board Meeting to consider these results will be communicated in due course, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

This announcement follows recent financial updates. For Q2 FY26, the company reported revenue from operations of ₹629.32 Lakhs, a 31.15% year-on-year increase, with a significantly narrowed net loss of ₹1.56 Lakhs. The first half of FY26 (H1 FY26) demonstrated a turnaround, achieving a Profit After Tax (PAT) of ₹41.73 Lakhs. The annual report for FY25 indicated a revenue decrease of 14.93% to ₹2543.34 Lakhs, but an improved net loss of ₹102.73 Lakhs compared to FY24.

In terms of corporate actions, the Board has accepted the resignation of Ms. Khushbu Prakashbhai Patel as Company Secretary and Compliance Officer, effective December 16, 2025. Previously, shareholders approved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second five-year term. The company's business overview indicates a focus on organic intermediates for pharmaceuticals, agriculture, and specialty chemicals, with risks including feedstock price volatility and market demand.

Link Pharma Chem Limited has released its financial results for Q1 FY26 and Q2 FY26, alongside its FY25 annual report and corporate updates.

Quarterly & Annual Performance:
For the quarter ended June 30, 2025 (Q1 FY26), the company reported revenue from operations of ₹781.48 Lakhs, an 11.66% decrease year-on-year. However, Profit After Tax (PAT) saw a substantial increase of 35.60% YoY to ₹40.19 Lakhs, with EPS rising by 35.8% YoY to ₹0.91. The company also achieved a quarter-on-quarter turnaround from a loss to a profit.

For the quarter ended September 30, 2025 (Q2 FY26), revenue from operations increased by 31.15% year-on-year to ₹629.32 Lakhs. The net loss for the quarter narrowed significantly to ₹1.56 Lakhs from a loss of ₹30.63 Lakhs in the prior year's corresponding quarter, with EPS turning positive at ₹0.03. For the first half of FY26 (H1 FY26), Link Pharma Chem achieved a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a substantial turnaround from a net loss of ₹0.99 Lakhs in H1 FY25, with EPS standing at ₹0.94.

The annual report for the financial year 2024-2025 indicated revenue of ₹2543.34 Lakhs, a 14.93% decrease from FY24. The net loss for FY25 was ₹102.73 Lakhs, an improvement from ₹136.29 Lakhs in FY24. Operational cash flow turned positive, and net debt reduced significantly.

Outlook & Discussion:
The company's outlook includes a focus on specialty chemicals. Identified risks include feedstock price volatility and market demand fluctuations. No specific forward-looking guidance on revenue or margins was provided in the announcements.

Financial Deep Dive & Ratios:
Historical company data indicates negative Return on Capital Employed (ROCE) and Return on Equity (ROE). While recent results show an improvement in profitability and narrowed losses, it is important to note the continued net loss in Q2 FY26. The annual report mentioned a reduction in net debt and positive operational cash flow.

Key Events:

• The Board approved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second term of five years, subject to shareholder approval. This was subsequently approved by shareholders at the 40th Annual General Meeting (AGM) held on September 9, 2025.
• All resolutions presented at the 40th AGM, including financial statement adoption and director re-appointments, were passed unanimously.
• Ms. Khushbu Prakashbhai Patel resigned from the post of Company Secretary and Compliance Officer, effective December 16, 2025.
• The company is exempt from disclosing Related Party Transactions for H1 FY26 due to its size.
• A trading window closure was implemented from October 1, 2025, until 48 hours after the declaration of Q2 FY26 results.

Link Pharma Chem Limited published newspaper advertisements in Business Standard (English) and Loksatta (Gujarati) on November 14, 2025. These advertisements presented extracts of the company's unaudited financial results for the second quarter (Q2 FY26) and the first half (H1 FY26) of the financial year ending September 30, 2025. For Q2 FY26, revenue from operations was ₹634.10 Lakhs, with a net profit after tax of ₹1.56 Lakhs and basic EPS of ₹0.03. For H1 FY26, the company reported a profit after tax of ₹41.73 Lakhs and a basic EPS of ₹0.94. The results reflect a significant operational recovery and turnaround, with narrowed losses and improved profitability year-on-year. The announcement also noted the upcoming resignation of the Company Secretary and Compliance Officer.

Link Pharma Chem Limited notified the BSE on November 13, 2025, that Regulation 23(9) of SEBI (LODR) Regulations, 2015, regarding the disclosure of Related Party Transactions, is not applicable to the company for the half-year ended September 30, 2025. This exemption is based on Regulation 15(2), which exempts companies with paid-up equity share capital not exceeding ₹10 Crore and net worth not exceeding ₹25 Crore. Link Pharma Chem confirmed it meets these financial criteria, referencing a BSE clarification from April 2022. This regulatory status was communicated alongside the announcement of the company's Q2 FY26 and H1 FY26 unaudited financial results. For Q2 FY26, revenue increased by 31.15% year-on-year to ₹629.32 Lakhs, with a narrowed net loss. H1 FY26 achieved a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a substantial turnaround from a net loss in the previous year, with EPS at ₹0.94. Despite these performance improvements, the company's overall size means it is not obligated to provide detailed RPT disclosures.

Link Pharma Chem Limited has announced the resignation of its Company Secretary and Compliance Officer, Ms. Khushbu Prakashbhai Patel, citing better prospects outside the organisation. Her resignation was accepted by the board on November 13, 2025, and she will be relieved from her duties effective the closure of business hours on Tuesday, December 16, 2025. This development follows the company's financial reporting for the second quarter (Q2 FY26) and the first half (H1 FY26) of the financial year ending September 30, 2025.

In Q2 FY26, Link Pharma Chem reported revenue from operations of ₹629.32 Lakhs, an increase of 31.15% year-on-year from ₹479.82 Lakhs in Q2 FY25. The net loss for the quarter narrowed significantly to ₹1.56 Lakhs, an improvement from a loss of ₹30.63 Lakhs in the prior year's corresponding quarter, with Earnings Per Share (EPS) turning positive at ₹0.03. For the first half of FY26, the company achieved a Profit After Tax (PAT) of ₹41.73 Lakhs, marking a substantial turnaround from a net loss of ₹0.99 Lakhs in H1 FY25, accompanied by an EPS of ₹0.94.

Earlier, for Q1 FY26, the company had reported revenue of ₹781.48 Lakhs (down 11.7% YoY) and PAT of ₹40.19 Lakhs (up 35.6% YoY), with an EPS of ₹0.91. The annual report for FY25 indicated a revenue of ₹2543.34 Lakhs (down 14.93% YoY) and an improved net loss compared to FY24.

Regulatory updates include the submission of a Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, on October 10, 2025, confirming compliant securities dematerialisation. The company also informed about the closure of its trading window effective October 1, 2025, in compliance with insider trading regulations, which will reopen 48 hours after the declaration of Q2/H1 FY26 results.

Link Pharma Chem Limited's Board of Directors, in a meeting on November 13, 2025, approved the unaudited financial results for the quarter and half-year ended September 30, 2025. For Q2 FY26, revenue from operations was ₹629.32 Lakhs, a 31.15% year-on-year increase from ₹479.82 Lakhs in Q2 FY25. The net loss for the quarter narrowed substantially to ₹1.56 Lakhs, an improvement from a loss of ₹30.63 Lakhs in Q2 FY25, with EPS turning positive at ₹0.03 from ₹(0.69) YoY. Quarter-on-quarter, revenue decreased by 19.47% from ₹781.48 Lakhs in Q1 FY26, and the company shifted from a profit of ₹40.19 Lakhs in Q1 FY26 to a loss in Q2 FY26. For the first half of FY26, the company reported a Profit After Tax (PAT) of ₹41.73 Lakhs, a significant turnaround from a net loss of ₹0.99 Lakhs in H1 FY25. The EPS for H1 FY26 was ₹0.94, compared to ₹(0.02) in H1 FY25. In management changes, the Board accepted the resignation of Ms. Khushbu Prakashbhai Patel as Company Secretary and Compliance Officer, effective December 16, 2025, citing better career prospects. The results were accompanied by a Limited Review Report from statutory auditors CNK & Associates LLP, confirming no material misstatements were found.

Link Pharma Chem Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025, on November 13, 2025. In Q2 FY26, revenue from operations rose 31.15% year-on-year to ₹629.32 Lakhs, while the net loss narrowed significantly to ₹1.56 Lakhs from ₹30.63 Lakhs in Q2 FY25. The Earnings Per Share (EPS) turned positive at ₹0.03, compared to ₹(0.69) in the prior year period. For the first half of FY26, revenue grew 3.40% year-on-year to ₹1,410.80 Lakhs, and the company reported a Profit After Tax (PAT) of ₹41.73 Lakhs, a marked improvement from a net loss of ₹0.99 Lakhs in H1 FY25, with EPS at ₹0.94. The balance sheet as of September 30, 2025, showed total assets of ₹2,566.43 Lakhs and total equity of ₹1,307.23 Lakhs. Total borrowings increased to ₹809.33 Lakhs, resulting in a higher debt-to-equity ratio. Cash flow from operations for H1 FY26 decreased to ₹118.89 Lakhs YoY, while investing activities saw increased outflows due to capital expenditure. Notably, Ms. Khushbu Prakashbhai Patel has resigned as Company Secretary and Compliance Officer, effective December 16, 2025. Regulatory updates include the closure of the trading window from October 1, 2025, and the submission of a confirmation certificate for share dematerialisation.

Link Pharma Chem Limited has announced an upcoming Board Meeting scheduled for Thursday, November 13, 2025. The primary purpose of this meeting is to consider and approve the unaudited financial results for both the second quarter and the first half of the financial year, both of which concluded on September 30, 2025. This announcement serves as an intimation of the results approval process, rather than a disclosure of the results themselves. No actual financial performance figures, revenue, profit, margins, or EPS are provided in this communication. Similarly, there is no management guidance or commentary on future outlook, growth drivers, or risks shared. The company also confirmed that its trading window, which prohibits trading by designated persons, will remain closed. This closure began on October 1, 2025, and will continue until 48 hours after the official declaration of the unaudited financial results. No information regarding specific orders, expansions, penalties, product launches, or regulatory updates was included in this filing.

The provided news comprises two official communications concerning Link Pharma Chem Limited's compliance with securities regulations. On October 10, 2025, Link Pharma Chem Limited, identified by BSE Scrip Code 524748, formally informed the Bombay Stock Exchange (BSE) about the submission of a Confirmation Certificate. This certificate is required under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, and pertains to the operational activities of the company for the quarter that concluded on September 30, 2025. The company attached the certificate it received from its Registrar and Share Transfer Agent (RTA), M/s. MUFG Intime India Private Limited (formerly Link Intime India Private Limited).

The accompanying certificate, dated October 4, 2025, from MUFG Intime India Private Limited, is addressed to the Compliance Officer and Company Secretary of Link Pharma Chem Limited. Its primary purpose is to confirm that the RTA has processed all securities received from depository participants for dematerialisation during the quarter ended September 30, 2025. The confirmation specifies that these securities were accurately confirmed (either accepted or rejected) to the depositories and that the securities comprising these certificates are duly listed on the stock exchanges where Link Pharma Chem Limited's shares are already traded.

Furthermore, the RTA explicitly stated that the physical share certificates received for the purpose of dematerialisation have undergone due verification, have been mutilated and cancelled, and that the names of the respective depositories have been substituted in the company's register of members as the registered owners within the timelines stipulated by SEBI regulations.

This filing is a standard regulatory requirement aimed at ensuring the integrity and transparency of the securities settlement system. It assures investors and regulators that the company's share transfer and dematerialisation processes are being managed efficiently and in compliance with SEBI guidelines, thereby safeguarding shareholder interests and maintaining the smooth functioning of the stock market.

Crucially, this announcement does not contain any information related to the company's financial performance, such as quarterly or annual revenue, profit figures, margins, or Earnings Per Share (EPS). It also does not provide any management guidance, outlook on future growth, or commentary on strategic initiatives. Likewise, there are no details concerning new orders, major expansions, product launches, penalties, or significant balance sheet or cash flow changes. Therefore, the impact on an investor's decision-making is minimal, being purely a procedural compliance update.

Link Pharma Chem Limited, through a formal intimation to the Department of Corporate Services at BSE Limited, has announced the closure of its trading window for dealing in the company's securities. The trading window will commence its closure from October 1, 2025. This decision is in adherence to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's own established Code of Conduct for regulating, monitoring, and reporting trading activities by designated persons and their immediate relatives.

The trading window is set to remain closed until 48 hours after the formal declaration of the unaudited financial results for both the quarter and the half-year period ending September 30, 2025. The company has assured that the date for the Board Meeting, where these crucial financial results will be deliberated and approved, will be communicated in due course. This standard regulatory practice is implemented to ensure fairness and transparency in the stock market, preventing any potential misuse of unpublished price-sensitive information by insiders. Investors and designated personnel are advised to note this closure period for any transactions involving the company's shares.

Link Pharma Chem Limited convened its 40th Annual General Meeting (AGM) on Tuesday, September 9, 2025, via Video Conferencing (VC)/ Other Audio Video Means (OAVM). The meeting concluded with the passing of all four resolutions put forth to the shareholders.

The first resolution, an Ordinary Resolution, pertained to the consideration and adoption of the Audited Financial Statements for the Financial Year ended March 31, 2025, along with the accompanying Reports of the Board of Directors and Auditors. This resolution was passed with 100% of the votes polled in favour, with no votes against. Promoters and Promoter Group held 2,179,760 votes polled (95.3349% of outstanding shares), all in favour. Public-Non Institution shareholders polled 65,272 votes (3.0311% of outstanding shares), also all in favour. Total votes polled were 2,245,032 (50.5573% of outstanding shares), with 100% in favour.

The second resolution, also an Ordinary Resolution, concerned the appointment of a director in place of Mr. Rishikesh Thakur, who retires by rotation and offers himself for re-appointment. Promoters and Promoter Group shareholders, who are interested in this agenda item, voted unanimously in favour, casting 2,179,760 votes in favour out of 2,179,760 polled (100% of votes polled). Public-Non Institution shareholders cast 65,272 votes in favour out of 65,272 polled (100% of votes polled). The resolution passed with 100% favour on votes polled.

The third resolution was an Ordinary Resolution to ratify the remuneration of the Cost Auditors for the financial year 2025-2026. Similar to the first resolution, this was passed with 100% of the votes polled in favour. The voting pattern was identical to Resolution 1, with Promoters and Promoter Group and Public-Non Institution shareholders voting overwhelmingly in favour.

Finally, the fourth resolution, a Special Resolution, was for the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director. This resolution also received unanimous approval from shareholders, with 100% of the votes polled in favour. The voting distribution mirrored that of the previous resolutions, reflecting strong shareholder consensus on the company's governance and board appointments.

No invalid votes were recorded for any of the resolutions across all categories of shareholders. The company secretary confirmed that the results were submitted to BSE Limited. The total number of shareholders on the record date was 6166. The AGM was held through Video Conferencing, with 4 promoters and 40 public shareholders attending via video conferencing.

Link Pharma Chem Limited disclosed on September 9, 2025, that its shareholders approved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director (Non-Executive) for a second term. The re-appointment is for a period of five consecutive years, commencing from September 14, 2025, and concluding on September 13, 2030. Mrs. Ghai holds a Bachelor of Science degree (completed 1997) and a Post Graduate Diploma in Business Management (PGDBM) (completed 1998). She possesses extensive experience in education and general administration. The company confirmed that Mrs. Ghai is not related to any directors, Key Managerial Personnel, or promoters and meets all independence criteria as per the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015, read with the relevant SEBI circular concerning changes in Directors.

Link Pharma Chem Limited conducted its 40th Annual General Meeting (AGM) on Tuesday, September 9, 2025. The meeting, held through Video Conferencing (VC)/Other Audio Video Means (OAVM), saw shareholders vote on four resolutions. The company submitted the voting results and the scrutinizer's report to the BSE. All resolutions were passed by the members with the requisite majority.

Resolution 1 involved the consideration and adoption of the Audited Financial Statements for the Financial Year ended March 31, 2025, along with the Board of Directors' and Auditors' reports. This ordinary resolution was passed with 100% of the votes polled in favour.

Resolution 2 concerned the appointment of a director in place of Mr. Rishikesh Thakur, who retires by rotation and offers himself for re-appointment. This ordinary resolution also received unanimous approval with 100% votes in favour.

Resolution 3 was for the ratification of remuneration of the Cost Auditors for the financial year 2025-2026. Shareholders approved this ordinary resolution with 100% of the votes polled in favour.

Resolution 4 involved the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director, a special resolution. This was also passed unanimously with 100% votes in favour.

Across all resolutions, the Promoter and Promoter Group, holding 2,286,425 shares, and Public Non-Institutions, holding 2,153,443 shares, participated. A total of 2,245,032 votes were polled, representing 50.5573% of the outstanding shares for the total. No invalid votes were reported for any category. The outcome signifies strong shareholder backing for the company's governance and management decisions.

Link Pharma Chem Limited has disclosed the summary of the proceedings of its 40th Annual General Meeting (AGM), held virtually on September 9, 2025. The meeting commenced at 11:40 a.m. and concluded at 12:10 p.m., with 44 members attending via Video Conferencing (VC). Key attendees included directors, management personnel (CFO, Company Secretary), and statutory/secretarial auditors. Mr. Rishikesh Thakur, Managing Director, chaired the meeting, noting the absence of the designated Chairman, Mr. Satish G. Thakur, due to health reasons.

The Company Secretary confirmed the distribution of the Notice convening the AGM and the Annual Report for the Financial Year 2024-2025 to shareholders. The Audited Financial Statements for the Financial Year ended March 31, 2025, along with the Board and Auditors' reports (which had no qualifications), were taken as read. Specific financial figures, such as revenue, PAT, margins, or EPS, were not detailed in this summary. Similarly, no specific management guidance numbers or street versus analyst expectations were provided.

During the AGM, the Chairman presented an overview of the company's performance for FY 2024-2025 and its future outlook. However, detailed commentary on growth drivers, risks, or strategy shifts was not included in the disclosure.

The following businesses were transacted:

• Ordinary Business: Adoption of Audited Financial Statements for FY ended March 31, 2025, and the Reports of the Board of Directors and Auditors.
• Ordinary Business: Re-appointment of Mr. Rishikesh Thakur as a director retiring by rotation.
• Special Business: Ratification of remuneration for the Cost Auditors for FY 2025-2026.
• Special Business: Re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director.

A 'Questions & Answers' session followed, where the Managing Director responded to queries from three shareholders. The company had provided remote e-voting facilities prior to the AGM, and in-meeting e-voting was also available. A scrutinizer has been appointed to compile the e-voting results, which will be submitted and publicly disclosed.

Link Pharma Chem Limited has notified the stock exchange (BSE) regarding the dispatch of its Annual Report for the financial year 2024-2025 to shareholders who have not provided their email addresses. The company's 40th Annual General Meeting (AGM) is scheduled for Tuesday, September 9, 2025, at 11:30 AM IST, to be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM). Key dates include a cut-off for e-voting and AGM participation on September 2, 2025, with remote e-voting available from September 6 to September 8, 2025. The web-link for the Annual Report 2024-2025 is provided on the company's website. Additionally, the company reminded shareholders holding physical securities about the SEBI mandate to update KYC details for seamless payment processing.

On August 14, 2025, Omkar Pharmachem Limited announced its standalone unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), showcasing exceptional performance. The company reported a dramatic increase in total income from operations to ₹1008.37 lakh, a surge of approximately 20,500% compared to ₹4.90 lakh in the same quarter last year (Q1 FY25). Quarter-on-quarter, revenue grew by an astounding 6573% from ₹13.50 lakh in Q4 FY25. Net profit after tax also saw substantial growth, reaching ₹20.09 lakh in Q1 FY26, a 310% increase YoY from ₹4.90 lakh in Q1 FY25. QoQ, net profit surged by 657% from ₹2.66 lakh in Q4 FY25. The Earnings Per Share (EPS) followed suit, standing at ₹0.1992 for Q1 FY26, up 310% YoY from ₹0.0486 in Q1 FY25 and up 654% QoQ from ₹0.0264 in Q4 FY25. The company's Q1 FY25 performance, particularly revenue and margins, appeared to be based on a very low operational base or significant adjustments, leading to unusually high percentage margins in that period. Separately, Link Pharma Chem Limited issued a newspaper advertisement on August 14, 2025, detailing the notice for its 40th Annual General Meeting to be held on September 09, 2025, through video conferencing, also informing about e-voting and book closure.

Link Pharma Chem Limited has issued a notice for its 40th Annual General Meeting (AGM), scheduled to be held on Tuesday, September 9, 2025, at 11:30 AM IST. The meeting will be conducted entirely through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in line with SEBI and MCA circulars. The agenda comprises Ordinary Business, notably the adoption of the Audited Financial Statements for the Financial Year ended March 31, 2025, along with the reports of the Board of Directors and Auditors. It also includes the re-appointment of Mr. Rishikesh Thakur, who retires by rotation. Special Business on the agenda features the ratification of remuneration for the appointed Cost Auditors for the financial year 2025-2026 and the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second term commencing September 14, 2025. The company has provided extensive instructions for shareholders to participate in the meeting and cast their votes through remote e-voting, which is open from September 6 to September 8, 2025, with September 2, 2025, as the cut-off date.

Link Pharma Chem Limited has submitted its Annual Report for the financial year 2024-2025, along with the Notice for its 40th Annual General Meeting (AGM). The company reported a revenue from operations of ₹2543.34 Lacs for FY25, a 14.93% decrease from ₹2989.77 Lacs in FY24, attributed to stiff market competition and sluggish demand. However, the net loss for the year narrowed to ₹102.73 Lacs from ₹136.29 Lacs in the previous year, indicating improved cost management and lower finance costs. Basic EPS also improved from a loss of ₹3.07 to ₹(2.31). The company's outlook involves developing new products and focusing on specialty chemicals for better margins, while risks include feedstock price volatility and market demand. Financially, the company saw a significant reduction in net debt from ₹842.28 Lacs to ₹568.10 Lacs, improving its Debt-Equity ratio to 0.46 from 0.67. Operating cash flow turned positive at ₹268.59 Lacs, a substantial improvement from the previous year's negative cash flow. The 40th AGM is scheduled for September 9, 2025, to be conducted via Video Conferencing.

Link Pharma Chem Limited announced its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), comparing performance against the quarter ended June 30, 2024 (Q1 FY25).

Quarterly Results:
The company reported a total income from operations of Rs. 911.80 Lacs for Q1 FY26, an increase of 13.63% year-on-year from Rs. 802.40 Lacs in Q1 FY25.
In terms of profitability, the net loss for the period after tax and exceptional items saw a significant reduction. For Q1 FY26, the net loss was Rs. -39.27 Lacs, which is a 49.34% improvement from the Rs. -77.65 Lacs loss reported in Q1 FY25.
The Earnings Per Share (EPS) demonstrated a strong turnaround, moving from a negative Rs. -2.31 in Q1 FY25 to a positive Rs. 0.91 in Q1 FY26, representing a 194.81% YoY increase. Total comprehensive income also showed improvement, with the net loss decreasing from Rs. -72.34 Lacs to Rs. -35.02 Lacs YoY.

Financials & Ratios: The provided extract focuses solely on the income statement highlights for the quarter. No information is available regarding EBITDA, EBIT, margins, balance sheet items, cash flow statements, debt positions, or key financial ratios.

Outlook & Guidance: No management guidance, outlook statements, or concall commentary were part of this announcement.

Key Events: The announcement also contained a notice for Gujarat Narmada Valley Fertilizers & Chemicals Limited (GNFC) regarding its 49th Annual General Meeting (AGM) scheduled for September 09, 2025, along with details for shareholders on updating their contact and banking information for AGM participation. Other articles in the newspaper snippet covered unrelated topics such as a police action in Vadodara, US tariffs on Indian exports, and general stock market sentiment, none of which are directly company-specific financial news.

Link Pharma Chem Limited has announced the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director (Non-Executive). This decision was approved by the company's Board of Directors on August 1, 2025, following a recommendation from the Nomination and Remuneration Committee. The re-appointment is for a second consecutive term, spanning five years, commencing from September 14, 2025, and concluding on September 13, 2030. This move is contingent upon the approval of the shareholders at the forthcoming general meeting. The company has confirmed that Mrs. Ghai meets all the requisite independence criteria as stipulated by the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Furthermore, she is not related to any of the company's Directors, Key Managerial Personnel, or Promoters. Mrs. Ghai brings to the board a strong academic background, holding a first-class Bachelor of Science degree (1997) and a Post Graduate Diploma in Business Management (PGDBM) (1998), complemented by considerable experience in education and general administration. This filing is a routine corporate governance update.

The Board of Directors of Link Pharma Chem Limited, in its meeting held on August 1, 2025, approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26).

Quarterly Results (Q1 FY26):

• Revenue from operations: ₹781.48 Lakhs. This represents an 11.7% decrease year-on-year from ₹884.63 Lakhs in Q1 FY25, but a 21.2% increase quarter-on-quarter from ₹644.66 Lakhs in Q4 FY25.
• Total Income: ₹802.40 Lakhs, down from ₹911.80 Lakhs YoY and up from ₹656.45 Lakhs QoQ.
• Profit After Tax (PAT): ₹40.19 Lakhs. This is a significant improvement of 35.6% year-on-year from ₹29.64 Lakhs in Q1 FY25 and a strong turnaround from a loss of ₹35.02 Lakhs in Q4 FY25.
• Earnings Per Share (EPS): ₹0.91, showing a year-on-year growth of 35.8% from ₹0.67 in Q1 FY25 and a substantial recovery from ₹-0.79 in Q4 FY25.
• Margins: The PAT margin for Q1 FY26 is approximately 5.1%. Specific EBITDA or EBIT figures are not disclosed in this filing.
• Exceptional Items: The company reported deferred tax adjustments. For Q1 FY26, deferred tax expense was ₹10.78 Lakhs, compared to ₹6.39 Lakhs in Q1 FY25. In the previous quarter (Q4 FY25), there was a deferred tax benefit of ₹-15.81 Lakhs. The prior year-ended (FY25) figures show a deferred tax credit of ₹-40.08 Lakhs.

Director Re-appointment:
The board also approved the re-appointment of Mrs. Rachna Manav Ghai (DIN:08885422) as a Woman Independent Director. Her second term will be for five consecutive years, commencing from September 14, 2025, to September 13, 2030, subject to shareholder approval at the upcoming General Meeting. Mrs. Ghai holds a BSc and PGDBM and has expertise in education and general administration. She is not related to any other director on the board.

Financials Overview:

• Paid-up Equity Share Capital: Remains constant at ₹444.06 Lakhs.
• Other Equity: ₹822.15 Lakhs.
• Balance Sheet/Cash Flow: Detailed balance sheet, debt, or cash flow information is not provided in this announcement.
• Ratios: EPS figures are available. Other key ratios like ROE, ROCE, Debt-to-Equity are not reported.

Outlook & Guidance:
No management guidance or outlook commentary is available in this filing.

Link Pharma Chem Limited announced its unaudited financial results for the first quarter ended June 30, 2025 (Q1 FY26) and the re-appointment of Mrs. Rachna Manav Ghai as an Independent Director. For Q1 FY26, Revenue from operations stood at ₹781.48 Lakhs, marking an 11.66% decrease year-on-year (YoY) from ₹884.63 Lakhs in Q1 FY25, but a 21.22% increase quarter-on-quarter (QoQ) from ₹644.66 Lakhs in Q4 FY25. Total Income was ₹802.40 Lakhs, down 11.99% YoY from ₹911.80 Lakhs in Q1 FY25, while QoQ it increased by 22.23% from ₹656.45 Lakhs in Q4 FY25. The company reported a Profit After Tax (PAT) of ₹40.19 Lakhs, a substantial 35.60% growth YoY from ₹29.64 Lakhs in Q1 FY25. Quarter-on-quarter, Link Pharma Chem achieved a significant turnaround, moving from a loss of ₹(35.02) Lakhs in Q4 FY25 to a profit in Q1 FY26. The Earnings Per Share (EPS) for Q1 FY26 was ₹0.91, up 35.82% YoY from ₹0.67 in Q1 FY25, and improved from ₹(0.79) QoQ. The PAT margin improved to 5.01% in Q1 FY26 from 3.25% in Q1 FY25. The company's paid-up equity share capital is ₹444.06 Lakhs, with Other Equity at ₹822.15 Lakhs. No management guidance or concall commentary was provided in this disclosure. Key events include the Board's approval of the Q1 FY26 results and the re-appointment of Mrs. Rachna Manav Ghai as a Woman Independent Director for a second five-year term (September 14, 2025, to September 13, 2030), pending shareholder approval. The company operates in a single segment: 'Manufacture and Sale of Chemicals'.